ClinicalTrials.gg
CompletedNCT03078582Updated Jul 27, 2022Results posted

Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients

A Phase 2 interventional study of Zilucoplan (RA101495) in Paroxysmal Nocturnal Hemoglobinuria (PNH), sponsored by Ra Pharmaceuticals. Completed at 12 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-07-27.

Sponsored by Ra Pharmaceuticals (part of UCB S.A.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Hemoglobinuria, Paroxysmal with a site in Australia — 2 open to participants now, 3 under way, none of them phase 3. Hemoglobinuria, Paroxysmal · Australia.

Enrollment
10th of 12
26 · median 80
Started
2017
with 2 others
Phase 2
2 of 15
none open now
Registered
8th of 15
by date
Lead sponsor
1 of 15
Ra Pharmaceuticals

Among the 15 studies in Hemoglobinuria, Paroxysmal with a site in Australia, this one is the 10th largest by enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2017, is one of 2 in phase 2, and was the 8th registered.

Hemoglobinuria, Paroxysmal

191 studies on the registry are indexed under Hemoglobinuria, Paroxysmal; 49 are open to participants now.

Browse Hemoglobinuria, Paroxysmal studies →

Open to participants now

2 of the 15 studies in Hemoglobinuria, Paroxysmal with a site in Australia are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 30 Hemoglobinuria, Paroxysmal studies recruiting now, 14 (47%) set no upper age limit and 12 (40%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Hemoglobinuria, Paroxysmal with a site in Australia, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the safety and efficacy of zilucoplan (RA101495) in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). There will be two groups of patients in the study: the first group will include patients who have never received eculizumab for treatment of PNH. The second group will include patients who have received treatment with eculizumab for at least 6 months prior to the study. Patients will be treated with RA101495 for 12 weeks.

03

Conditions studied

  • Paroxysmal Nocturnal Hemoglobinuria (PNH)

Keywords

  • PNH
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of PNH by flow cytometry
  • For treatment naive patients: subjects must not have received treatment with eculizumab prior to or during the Screening Period and must have a lactate dehydrogenase (LDH) level ≥2 times the (xULN) during Screening
  • For patients who previously received eculizumab: subjects must have received treatment with eculizumab for at least 6 months prior to Screening

Exclusion criteria

Exclusion Criteria:

  • History of meningococcal disease
  • Current systemic infection or suspicion of active bacterial infection
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Zilucoplan (RA101495) treatment naive

    0.3mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC (treatment naïve)

    Drug: Zilucoplan (RA101495)

  • Experimental
    Zilucoplan (RA101495) previously on eculizumab

    0.3mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC (previously on eculizumab)

    Drug: Zilucoplan (RA101495)

Interventions

  • 0.3mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC

06

What researchers measure

Primary outcomes

  1. Change-from-baseline in Serum Lactate Dehydrogenase (LDH) Level.

    The primary efficacy endpoint is the change-from-baseline in serum LDH levels during this period, defined as the mean LDH values of Weeks 6, 8, 10, and 12 minus the baseline value of LDH.

    Time frame: Through Week 12 of the study

Secondary outcomes

  1. Changes From Baseline in Bilirubin Values

    Changes from baseline at each of the scheduled post-baseline time-points

    Time frame: Through Week 12 of the study

  2. Total Hemoglobin

    Changes from baseline at each of the scheduled post-baseline time-points

    Time frame: Through Week 12 of the Study

  3. Changes From Baseline in Free Hemoglobin Values

    Changes from baseline at each of the scheduled post-baseline time-points

    Time frame: Through Week 12 of the study

  4. Haptoglobin Values

    Changes from baseline at each of the scheduled post-baseline time-points

    Time frame: Through Week 12 of the Study

  5. Reticulocyte Values

    Changes from baseline at each of the scheduled post-baseline time-points

    Time frame: Through Week 12 of the Study

  6. Hemoglobinuria Values

    Changes from baseline at each of the scheduled post-baseline time-points; Hemoglobinuria was assessed using a urine colorimetric scoring system with a score of 1 through 10. Where 1 represents no hemoglobinuria and 10 represents maximum hemoglobinuria.

    Time frame: Through Week 12 of the Study

07

Results

Posted Mar 10, 2020

Participant flow

Participant flow — Overall Study
MilestoneCohort A (Treatment Naive)Cohort B (Previously on Eculizumab)
Started1016
Completed108
Not completed08
Withdrew: Adverse event08

Outcome measures

PrimaryChange-from-baseline in Serum Lactate Dehydrogenase (LDH) Level.

The primary efficacy endpoint is the change-from-baseline in serum LDH levels during this period, defined as the mean LDH values of Weeks 6, 8, 10, and 12 minus the baseline value of LDH.

Time frame:
Through Week 12 of the study
Reported as:
Mean · U/L
Change-from-baseline in Serum Lactate Dehydrogenase (LDH) Level.
U/LCohort A (Treatment Naive)Cohort B (Previously on Eculizumab)
Change-from-baseline in Serum Lactate Dehydrogenase (LDH) Level.-695.2 ± 589.2216.7 ± 209.2
SecondaryChanges From Baseline in Bilirubin Values

Changes from baseline at each of the scheduled post-baseline time-points

Time frame:
Through Week 12 of the study
Reported as:
Mean · umol/L
Changes From Baseline in Bilirubin Values
umol/LCohort A (Treatment Naive)Cohort B (Previously on Eculizumab)
Week 11.3 ± 7.21.9 ± 4.5
Week 23.1 ± 7.74.4 ± 6.5
Week 34.4 ± 9.06.8 ± 7.5
Week 44.0 ± 6.74.3 ± 6.5
Week 64.1 ± 7.43.8 ± 7.8
Week 84.0 ± 6.14.4 ± 9.9
Week 105.7 ± 10.91.5 ± 6.1
Week 124.6 ± 11.80.9 ± 4.5
SecondaryTotal Hemoglobin

Changes from baseline at each of the scheduled post-baseline time-points

Time frame:
Through Week 12 of the Study
Reported as:
Mean · g/L
Total Hemoglobin
g/LCohort A (Treatment Naive)Cohort B (Previously on Eculizumab)
Week 1-1.5 ± 10.4-0.7 ± 7.1
Week 21.6 ± 7.40.9 ± 5.4
Week 34.3 ± 9.5-1.1 ± 9.0
Week 42.7 ± 10.5-0.9 ± 5.1
Week 63.6 ± 9.8-1.4 ± 5.3
Week 83.1 ± 9.6-1.0 ± 7.6
Week 104.5 ± 8.8-1.3 ± 8.7
Week 126.9 ± 10.60.5 ± 7.2
SecondaryChanges From Baseline in Free Hemoglobin Values

Changes from baseline at each of the scheduled post-baseline time-points

Time frame:
Through Week 12 of the study
Reported as:
Mean · mg/dL
Changes From Baseline in Free Hemoglobin Values
mg/dLCohort A (Treatment Naive)Cohort B (Previously on Eculizumab)
Week 1-7.84 ± 8.373.55 ± 18.51
Week 2-8.31 ± 9.07-1.00 ± 11.66
Week 3-5.65 ± 10.25-0.21 ± 3.87
Week 4-7.57 ± 8.1216.90 ± 50.64
Week 6-8.24 ± 9.19-3.53 ± 10.66
Week 8-7.62 ± 9.07-2.39 ± 9.25
Week 10-7.60 ± 9.03-2.02 ± 10.06
Week 12-7.39 ± 10.10-2.23 ± 11.32
SecondaryHaptoglobin Values

Changes from baseline at each of the scheduled post-baseline time-points

Time frame:
Through Week 12 of the Study
Reported as:
Mean · g/L
Haptoglobin Values
g/LCohort A (Treatment Naive)Cohort B (Previously on Eculizumab)
Week 10.090 ± 0.2850.010 ± 0.019
Week 20.080 ± 0.253-0.003 ± 0.007
Week 30.006 ± 0.019-0.003 ± 0.007
Week 40.012 ± 0.038-0.064 ± 0.180
Week 60.000 ± 0.000-0.064 ± 0.180
Week 80.004 ± 0.013-0.064 ± 0.180
Week 100.000 ± 0.000-0.064 ± 0.180
Week 120.000 ± 0.000-0.064 ± 0.180
SecondaryReticulocyte Values

Changes from baseline at each of the scheduled post-baseline time-points

Time frame:
Through Week 12 of the Study
Reported as:
Mean · 10^12 cells/L (SI Units)
Reticulocyte Values
10^12 cells/L (SI Units)Cohort A (Treatment Naive)Cohort B (Previously on Eculizumab)
Week 1-0.0113 ± 0.0494-0.0147 ± 0.0326
Week 2-0.0157 ± 0.05910.0022 ± 0.0279
Week 3-0.0099 ± 0.05840.0063 ± 0.0197
Week 4-0.0137 ± 0.04390.0004 ± 0.0289
Week 60.0000 ± 0.05380.0170 ± 0.0259
Week 8-0.0042 ± 0.06190.0050 ± 0.0346
Week 10-0.0060 ± 0.06080.0085 ± 0.0304
Week 12-0.0047 ± 0.05700.0061 ± 0.0166
SecondaryHemoglobinuria Values

Changes from baseline at each of the scheduled post-baseline time-points; Hemoglobinuria was assessed using a urine colorimetric scoring system with a score of 1 through 10. Where 1 represents no hemoglobinuria and 10 represents maximum hemoglobinuria.

Time frame:
Through Week 12 of the Study
Reported as:
Mean · score on a scale
Hemoglobinuria Values
score on a scaleCohort A (Treatment Naive)Cohort B (Previously on Eculizumab)
Week 1-0.2 ± 2.30.8 ± 1.8
Week 20.4 ± 2.20.1 ± 1.3
Week 30.3 ± 2.70.7 ± 1.8
Week 4-0.2 ± 2.00.4 ± 1.6
Week 60.3 ± 2.50.8 ± 2.3
Week 8-0.2 ± 2.30.3 ± 1.6
Week 100.3 ± 2.90.9 ± 1.6
Week 12-0.2 ± 2.90.0 ± 2.2

Adverse events

Collected over Through Week 12 of the study. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort A (Treatment Naive)0/10 (0%)2/10 (20%)10/10 (100%)
Cohort B (Previously on Eculizumab)0/16 (0%)1/16 (6.3%)15/16 (93.8%)
Most frequent serious events
Most frequent serious events
EventCohort A (Treatment Naive)Cohort B (Previously on Eculizumab)
PyrexiaGeneral disorders1/10—
Febrile nonhaemolytic transfusion reactionInjury, poisoning and procedural complications1/10—
Urinary tract InfectionInfections and infestations—1/16
Most frequent other events
Showing 10 of 55
Most frequent other events
EventCohort A (Treatment Naive)Cohort B (Previously on Eculizumab)
HaemolysisBlood and lymphatic system disorders0/107/16
HeadacheNervous system disorders1/107/16
Injection site bruisingGeneral disorders3/101/16
Upper respiratory tract infectionInfections and infestations3/101/16
Abdominal PainGastrointestinal disorders2/101/16
DizzinessNervous system disorders2/103/16
Oropharyngeal painRespiratory, thoracic and mediastinal disorders2/100/16
Abdominal Pain UpperGastrointestinal disorders0/103/16
FatigueGeneral disorders1/103/16
Back painMusculoskeletal and connective tissue disorders1/103/16

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Cohort A (Treatment Naive)Cohort B (Previously on Eculizumab)Total
<=18 years000
Between 18 and 65 years71118
>=65 years358
Age, Continuous
Age, Continuous(years)Cohort A (Treatment Naive)Cohort B (Previously on Eculizumab)Total
Mean59.4 ± 14.549.6 ± 18.553.4 ± 17.4
Sex: Female, Male
Sex: Female, Male(Participants)Cohort A (Treatment Naive)Cohort B (Previously on Eculizumab)Total
Female6713
Male4913
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort A (Treatment Naive)Cohort B (Previously on Eculizumab)Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American022
White101424
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Cohort A (Treatment Naive)Cohort B (Previously on Eculizumab)Total
New Zealand404
Canada101
Hungary112
Finland123
Denmark011
United Kingdom235
Australia055
Germany145
Weight
Weight(kg)Cohort A (Treatment Naive)Cohort B (Previously on Eculizumab)Total
Mean77.77 ± 20.6479.16 ± 14.8678.63 ± 16.92
Height
Height(cm)Cohort A (Treatment Naive)Cohort B (Previously on Eculizumab)Total
Mean168.25 ± 11.08171.10 ± 8.69170.00 ± 9.56
BMI
BMI(kg/m2)Cohort A (Treatment Naive)Cohort B (Previously on Eculizumab)Total
Mean27.30 ± 6.1526.95 ± 4.1427.08 ± 4.89
08

Study locations

12 sites
  • Investigative Site
    Gosford, New South Wales, Australia
  • Investigative Site
    Parkville, Australia
  • Investigative Site
    Toronto, Ontario, Canada
  • Investigative Site
    Copenhagen, Denmark
  • Investigative Site
    Helsinki, Finland
  • Investigative Site
    Essen, Germany
  • Investigative Site
    Ulm, Germany
  • Investigative Site
    Budapest, Hungary
  • Investigative Site
    Christchurch, New Zealand
  • Investigative Site
    Hamilton, New Zealand
  • Investigative Site
    Leeds, United Kingdom
  • Investigative Site
    London, United Kingdom
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2017 to primary completion in Mar 2018, 12 months.

Results were first posted in Mar 2020, 1 year 11 months after primary completion.

Of 26 industry-sponsored phase 2 interventional studies under Hemoglobinuria, Paroxysmal, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 25. This study's 12 months is below that.

Counting every sponsor, half of 34 studies reached it within 24 months; a quarter within 12 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2017
First posted
Mar 13, 2017
StartActual
Mar 8, 2017
Primary completionActual
Mar 28, 2018
CompletionActual
Mar 28, 2018
Results first posted
Mar 10, 2020
Last update
Jul 27, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03078582
Lead sponsor
Ra Pharmaceuticals
Responsible party
Sponsor
First posted
Mar 13, 2017
Start date
Mar 8, 2017
Primary completion
Mar 28, 2018
Completion
Mar 28, 2018
Results posted
Mar 10, 2020
Last update
Jul 27, 2022

Study contacts

Dr. Anita Hill
principal investigator · St James' Institute of Oncology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zilucoplan

Start the discussion